SERA PROGNOSTICS INC-A (SERA)

Company Profile

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 89 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The firm's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman carrying a single fetus during weeks 18 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth, and postpartum depression.

Company Info

SERA PROGNOSTICS INC-A

2749 E. Parleys Way, Suite 200

Salt Lake City UTAH

P: 18015050278

CEO: Gregory C. Critchfield

Employees: 89

Website: https://www.seraprognostics.com/